Kornimate/medical-research-clean huggingface dataset:
assistive device for hand osteoarthritis

Conditions: Hand Osteoarthritis

Summary: randomized clinical trial , blind for evaluators, to assess the effectiveness of a self-care program using assistive technology for treatment of hand osteoarthritis.

this program aims to: * encourage the use of assistive devices on a daily basis as the main form of joint protection. * encourage individual motivation, from the group in attendance, behavior change, developing the capacity of self-management of individuals of their health problems. will be held for 4 meetings with an average duration of 90 minutes. meeting 1: its proposal address the importance of self-care in the treatment of chronic diseases; knowing the oa of the hands and their main characteristics; recognize the importance of hand function for carrying out activities; understand the meaning of self-care and joint protection; motivation adherence to the program and behavior change. meeting 2: present assistive devices as a protection feature; teach joint protection techniques and energy conservation focusing on the assistive device; deliver and demonstrate the use of assistive devices. meeting 3:encouraging the adhesion of the techniques presented; making workshop for daily activities; verify the difficulties with devices use by the volunteers. meeting 4: strengthening guidance given in previous meetings; make closing with the group to in connection with the program; motivated to continue carrying out the activities at home.

Eligibility criteria:
inclusion criteria: * hand oa diagnosis according to the criteria of the american college of rheumatology (acr ) * be properly registered in the rheumatology clinic of hospital das clínicas exclusion criteria: * surgical treatment or infiltration in the hands, in the last 6 months; * treatment of occupational therapy and / or physical therapy, or use of any ta feature (assist device or stent) in the last 6 months; * diagnosis of another rheumatologic disease or musculoskeletal system that compromise the hands associated.

Keywords: hand osteoarthritis self care program assistive tecnology
feasibility of wb-ems in frail older people

Conditions: Frailty; Mobility Limitation

Summary: exercise in general and resistance training (rt) in particular have demonstrated positive effects on physical functioning and frailty. however, frail older people with functional impairments are among the least physically active and may have problems reaching high intensity levels. the use of special vests with integrated electrodes allows the simultaneous innervation of all large muscle groups by external electrical stimulation, inducing a high-intensity rt at low subjective effort level. this whole-body electromyostimulation (wb-ems) may be a feasible option inducing training stimuli for functionally impaired frail older people. this study aims at investigating the feasibility and safety of wb-ems in frail older people with functional limitations. to explore the effects of age and functional status, young and robust old reference groups will serve as comparators.


Eligibility criteria:
frail people inclusion criteria: * 75+ years * frail * able to walk 4m w/o walking aid * no prior wb-ems exposure exclusion criteria: * severe visual or hearing impairments * major cognitive impairment (mmse \<10) * medications with muscle-anabolic effects * medical conditions affecting trainability of muscles (e.g. myasthenia gravis, cushing syndrome, morbus mcardle) * surgery within past two months * history of rhabdomyolysis * medical conditions affecting sensation of electrical stimuli (e.g. severe polyneuropathy) * severe renal insufficiency (egfr\<30 ml/min/1.73m²) * electronic implants * acute or untreated abdominal wall or inguinal hernia robust people inclusion criteria: * 75+ years * robust * no prior wb-ems exposure exclusion criteria: * severe visual or hearing impairments * major cognitive impairment (mmse \<10) * medications with muscle-anabolic effects * medical conditions affecting trainability of muscles (e.g. myasthenia gravis, cushing syndrome, morbus mcardle) * surgery within past two months * history of rhabdomyolysis * medical conditions affecting sensation of electrical stimuli (e.g. severe polyneuropathy) * severe renal insufficiency (egfr\<30 ml/min/1.73m²) * electronic implants * acute or untreated abdominal wall or inguinal hernia younger people inclusion criteria: * 18-50 years * healthy * no prior wb-ems exposure exclusion criteria: * severe visual or hearing impairments * major cognitive impairment (mmse \<10) * medications with muscle-anabolic effects * medical conditions affecting trainability of muscles (e.g. myasthenia gravis, cushing syndrome, morbus mcardle) * surgery within past two months * history of rhabdomyolysis * medical conditions affecting sensation of electrical stimuli (e.g. severe polyneuropathy) * severe renal insufficiency (egfr\<30 ml/min/1.73m²) * electronic implants * acute or untreated abdominal wall or inguinal hernia * pregnancy
study of innovative strategies for mitral valve repair

Conditions: Congenital Mitral Insufficiency

Summary: the goal of this observational study is to compare the safety and effectiveness of a 3-steps standardized repair-oriented strategy with annuloplasty only in pediatric patients with mild to moderate mitral valve regurgitation. the main questions it aims to answer are: * can 3-steps standardized repair-oriented strategy improve both left ventricular and mitral valve function in pediatric patients with mild to moderate mitral valve regurgitation? * can surgical complications caused by the 3-steps standardized repair-oriented strategy be non-inferior (clinically acceptable) to annuloplasty only? participants will be assigned to either the standardized group (including subvalvular apparatus rehabilitation (leaflet plication if chordae absent on leaflet margin, mal-connected chordae resection if chordae mal-connected to leaflet body, papillary muscle splitting if short chordae or dysplastic or fused papillary muscle etc.), leaflets repair (leaflets plication if functional leaflet prolapse, leaflet cleft closure and patch augmentation for anatomical leaflet defect, etc.) and annuloplasty (posterior annuloplasty for annular dilatation and shallow leaflet coaptation, etc.)) or the annuloplasty group (annuloplasty only during mitral repair surgeries. additionally, echocardiography, electrocardiograms, and measurements of n-terminal pro-brain natriuretic peptide (nt-probnp) were conducted before the initiation of surgery and at 1 months, 3 months, and 6 months after mitral repair. researchers will compare the standardized group and the annuloplasty group to see if the recurrence rate of moderate to severe mitral valve regurgitation, as assessed by echocardiography after 6 months of surgery, is lower in the former than in the latter.


Eligibility criteria:
inclusion criteria: * \< 14 years old * had not undertake mitral valve surgery before * moderate to severe mitral regurgitation exclusion criteria: * moderate to severe mitral regurgitation which concommitant with other cardiac malformation which can not be correct or can only perform palliative surgery * concommitant with mitral stenosis * ischemic mitral regurgitation (for example, concommitant with anomalous origin of coronary artery) * barlow syndrome * dysplasia of mitral leaflet * complete/partial endocardial cushion defect * common atrioventricular valve * atrioventricular common channel * cardiomyopathy * other mitral valve surgery contraindications

Keywords: congenital heart disease mitral regurgitation mitral valve repair
sitafloxacin and ertapenem treatment for acute pyelonephritis caused by escherichia coli

Conditions: Infection Due to Escherichia Coli; Acute Pyelonephritis

Summary: the aim of the investigators' study was to evaluate oral and non carbapenem antimicrobial agents which can be used in outpatient for the treatment of non-bacteremic acute pyelonephritis caused by extended spectrum beta lactamase escherichia coli. this study was conducted to compare the clinical and bacteriological outcomes of patients with non-bacteremic acute pyelonephritis caused by extended spectrum beta lactamase escherichia coli who were treated with intravenous (iv) carbapenems followed by oral sitafloxacin or iv ertapenem.

a prospective randomized controlled trial of patients with a presumptive diagnosis of acute pyelonephritis caused by extended spectrum beta lactamase-producing pathogen was performed. carbapenems was initially given to all patients. after day 3, patients were randomized to receive either oral sitafloxacin (100 mg twice daily) or intravenous ertapenem. the regular course of treatment was completed within 10 days.

Eligibility criteria:
inclusion criteria: * age \>18 years * acute pyelonephritis by definition * positive urine culture for extended spectrum beta lactamase escherichia coli ≥105 colony forming unit/ml * voluntarily consented to be enrolled in the study exclusion criteria: * severe sepsis or septic shock * mixed organism of urine culture * positive blood culture * has other source of infection * has mechanical abnormality of urinary tract * immunocompromised conditions * retained foley's catheter * pregnancy or lactation * previous urinary tract infections within 4 weeks * contraindicated for fluoroquinolones and carbapenems

Keywords: sitafloxacin extended-spectrum ß-lactamase-producing escherichia coli treatment for acute pyelonephritis ertapenem
the smarter cardiomyopathy study

Conditions: Cardiomyopathies; Hypertrophic Cardiomyopathy; Dilated Cardiomyopathy

Summary: cardiomyopathies are diseases of the heart muscle. known genetic factors may account for some cardiomyopathy cases but there is still much to understand about the genetic and environmental causes and how the disease progresses. finding new ways to diagnose and treat cardiomyopathies could improve the health and well-being of patients with these conditions. this study will collect data from individuals with cardiomyopathy or related heart muscle disease, or with a possible genetic predisposition to cardiomyopathy, and follow them over time to observe the progress of their heart and health. this study will collect dna, blood samples, and detailed clinical \& lifestyle information at the start of the study, and data collected during routine healthcare visits over time. * learn what causes cardiomyopathy, and therefore how to treat it * understand why cardiomyopathy progresses differently in different people, to improve the ability to recognise who will benefit from different treatments at different times the investigators will collaborate with other centres internationally to collect a large of group of participants with similar cardiomyopathies, providing power to identify new pathways that cause disease and ways of predicting which participants are at risk of having more severe disease.


Eligibility criteria:
inclusion criteria: adults with the capacity to consent children with parental/guardian consent male and female meeting the following criteria: 1. patients with a confirmed diagnosis of cardiomyopathy or related condition 2. patients with a family member with cardiomyopathy, or a related condition 3. patients with a genetic variant that may predispose to cardiomyopathy, or a related condition exclusion criteria: patients without the capacity to provide informed consent
child and adolescent ocd outcomes from exposure and response prevention video teletherapy treatment

Conditions: Obsessive-Compulsive Disorder

Summary: this is a naturalistic, observational study of children and adolescents with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy.


Eligibility criteria:
inclusion criteria: * obsessive-compulsive disorder exclusion criteria: * none

Keywords: exposure and response prevention digital behavioral health remote treatment video therapy children adolescents
a clinical observation on neuropsychology and electrophysiology in headache patinets with myofascial trigger points

Conditions: Myofascial Trigger Points

Summary: to study the clinical characteristics of headache patients with pericranial myofascial trigger points(mtrps),and to explore the possible pathogenesis of mtrps,investigators hope to find the possible electrical biomarkers for clinical diagnosis and treatment, and to improve the effect of headache treatment.

a series of neuropsychological test scale including mini-mental state examination(mmse),hamilton anxiety rating scale(hama) and hamilton depression rating scale (hmad) were evaluated among all patients.the needle pole electromyography (emg) inspection were practiced on subjects with myofascial trigger points ,for analysing those electrophysiological characteristics.

Eligibility criteria:
inclusion criteria: * primary headache patients with pericranial myofascial trigger points. exclusion criteria: * cranial weeks muscle infection or trauma, medical history, physical examination, laboratory and imaging studies suggest secondary headache patients except cervicalheadache.

Keywords: headache neuropsychological tests myofascial trigger points electrophysiology
natural history of liver cirrhosis diagnosed by transient elastography in hiv/hcv-coinfected patients

Conditions: Liver Cirrhosis; Hepatocellular Carcinoma; HIV; HCV Coinfection

Summary: prospective multicenter cohort recruiting consecutive patients from 7 hospitals in andalusia, southern spain, according to following criteria: 1) hiv infection, 2) chronic active hcv infection, 3) older than 18 years, 4) new diagnosis of liver cirrhosis on the basis of a liver stiffness above 14 kilopascals, 5) no previous or concomitant decompensation of liver disease. patients are prospectively followed-up according to a uniform protocol of care. epidemiological, clinical and laboratory variables are periodically recorded. the primary outcomes are the emergence of a liver decompensation (including hepatocellular carcinoma), liver transplant or death. the predictors of these outcomes are analyzed.


Eligibility criteria:
inclusion criteria: * hiv infection * hcv chronic active infection (positive serum rna hcv at inclusion) * new diagnosis of cirrhosis on the basis of a liver stiffness equal or greater than 14 kilopascals. * no previous or concomitant decompensation of liver disease exclusion criteria: -

Keywords: hcv hiv liver cirrhosis hepatocellular carcinoma liver transplant liver stiffness transient elastography
cohort prospective study of children with head and neck cystic malformation who are treated with intracystic ok432

Conditions: CYSTIC MALFORMATION

Summary: cohort study evaluate the efficacy treatment with ok-432 in cystic malformation of the head and neck region. the malformations are macrocystic and the preevaluation will include ct/mri, us and blood tests. the injection will be in the or under us guided, maximal dose will be 0.2mg. the follow-up will be of short term - till 30 days post injection and long term - follow-up wil be till 2 years.

a cohort study, before the injection all the patients in the study will go through: 1. ct/mri 2. us to estimate the cyst size 3. cbc, pt, ptt, inr, aslo 4. ecg if the patient is qualified to the study the parent will sign on the inform consent, than the child will be photographed ap and lateral. the injection will be held in the or under us guidance with 18q20 gauge needle, first all the cyst contents will be sucked than the ok432 will be injected in. after the injection the child will stay for one night if it was general anesthesia and 4 hours in the case of local anesthesia. short term follow - 3-5 days with the phone, up: till 30 days from the injection with us, stills photo. long term follow-up: 6 months, 1 year, 2 years

Eligibility criteria:
inclusion criteria: * lymphatic malformation macrocystic or mixed with more then 50% macrocystic. * only in the head and neck area * time from operation at least 6 months exclusion criteria: * penicillin allergy * pregnancy * familial history of rf * post streptococcal glomerulonephritis * background illness-heart, kidney, lungs * fever \> 38.5c in the op day * urt infection * family history of pandas

Keywords: ok432, cystic malformation
effects of aliskiren/amlodipine versus amlodipine monotherapy on ankle-foot volume in hypertensive patients

Conditions: Hypertension

Summary: comparison between the effect of aliskiren/amlodipine combination with amlodipine monotherapy on ankle-foot volume in hypertensive patients. it will be enrolled male or female outpatients, aged 18-65 years.


Eligibility criteria:
inclusion criteria: * diastolic blood pressure \> 95 mmhg and \< 110 mmhg * systolic blood pressure \> 140 mmhg and \< 180 mmhg * no amlodipine therapy for the previous 6 months exclusion criteria: * diastolic blood pressure \> 110 mmhg and or * systolic blood pressure \> 180 mmhg * secondary hypertension * heart failure * diabetes mellitus * liver or kidney diseases

Keywords: aliskiren amlodipine hypertension ankle-foot volume mild and moderate hypertension
cancer genome study using samples from patients treated on clinical trial shr1020-shr-1210-ii-os

Conditions: Osteosarcoma

Summary: rationale: studying samples of tumor tissue from patients with advanced osteosarcoma refractory to chemotherapy in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to osteosarcma treatment combining anti-angiogenesis tyrosine kinase inhibitors and anti-pd-1 antibody. purpose: this research study is looking at the cancer genome using tumor samples from patients with advanced stage osteosarcoma treated on clinical trial shr1020-shr-1210-ii-os.

objectives: to investigate the clinical relevance of conducting comprehensive molecular analyses on clinically annotated high-quality tumor specimens from patients with advanced stage osteosarcoma. outline: this is a single-center study. biological specimens are collected from participating clinical site and analyzed by transcription profiling of rna and microrna; detection of dna copy number changes and chromosomal rearrangements; epigenetic modifications analyses; and sequencing of genomic segments, genes, and regulatory regions to assess sequence variation. clinical information associated with each specimen donor is also collected.

Eligibility criteria:
inclusion criteria: * diagnosis of high-grade osteosarcoma * refractory to chemotherapy and intended to receive famitinib and camrelizumab following the protocols of shr1020-shr-1210-ii-os * available tumor tissue samples collected before study drug and after first progression * must have matching frozen samples of normal tissue and blood exclusion criteria: * patients with concurrent malignancy; patients with prior or concurrent malignancy will be allowed as long as the treating physician considers it unlikely to impact the clinical outcome of the patient * serious medical illness including but not limited to uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction or cerebrovascular event with 6 months of registration, history of chronic active hepatitis or history of human immunodeficiency virus (hiv) or an active bacterial infection will not be eligible * pregnant or lactating women

Keywords: genomic biomarkers famitinib camrelizumab tumor mutation burden pd-l1 expression tcell-inflamed gene expression profile (gep)
locally delivered aloe vera gel in the treatment of chronic periodontitis patients with diabetes mellitus

Conditions: Diabetes Mellitus; Chronic Periodontitis

Summary: a study on the effect of locally delivered aloe vera gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis patients with controlled type ii diabetes mellitus.the evaluation of plaque index, gingival index, probing pocket depth, relative attachment level at baseline, 6 weeks and 3 months and glycosylated heamoglobin at baseline and 3 months.

aloe vera gel was locally delivered in the periodontal pockets of ≥ 5mm bilaterally in chronic periodontitis patients with diabetes under control.(hba1c-6.6-8.6%).the study design had two groups-one in which scaling and root planing and local delivery of aloe vera gel and the other only scaling and root planing. the evaluation of clinical parameters of pi, gi, ppd and ral at baseline, 6 weeks and 3 months. hba1c evaluated at baseline and 3 months.

Eligibility criteria:
inclusion criteria: 1. patients age 30 - 55 years from both genders. 2. patients with controlled type ii diabetes mellitus (hba1c \< 7%) with chronic periodontitis having ≥ 5mm periodontal pockets bilaterally atleast in one site. 3. patients on oral hypoglycaemic agents. 4. subjects who have not received periodontal therapy within preceding 6 months. 5. patients willing to comply with all study related procedures. exclusion criteria: 1. subjects who have received antibiotic treatment in the preceding 3 months. 2. history of prolonged use of antibiotics/ steroids/ immunosuppressive agents /aspirin/ anticoagulants/ other medications including any other herbal products. 3. pregnant or lactating women. 4. smokers. 5. history of systemic diseases like hypertension, hiv, bone metabolic disorders, radiation therapy, osteoporosis, immunosuppressive therapy, cancer etc.other than diabetes. 6. unwilling patients

Keywords: clinical trial
prevalence of pathogens in cerebrospinal fluid obtained from emergency department patients

Conditions: Meningoencephalitis; Other Syndromes Requiring Lumbar Puncture in Emergency Department

Summary: of all emergency room patients, persons presenting with encephalitis/meningitis syndrome of a potentially infectious nature are among those of greatest concern. routine clinical and laboratory evaluation of such patients involves screening for known infectious disease agents, selection of which is nonstandardized. progress in diagnostic technologies, especially molecular techniques based on genetic characteristics of potential pathogens, has greatly expanded the investigators capacity to evaluate specimens from patients for a much wider range of potential pathogens (bacterial, viral, fungal and parasitic agents). use of polymerase chain reaction (pcr) technology offers the possibility of identifying causative agents for the approximately 50% of all such presentations which go un-diagnosed. the investigators propose a study involving a collaboration between the emergency id net, a network of 10 geographically diverse university-affiliated urban emergency departments (coordinated by olive view-ucla medical center) and the centers for disease control and prevention (cdc), to use these new technologies to address this issue.


Eligibility criteria:
inclusion criteria: * age \> or = 3 months old * receiving a lumbar puncture in the emergency department as part of their standard care. exclusion criteria: * no csf available
remote ischemic preconditioning of dynamic cerebral autoregulation in healthy adults

Conditions: Ischemic Preconditioning

Summary: the purpose of this study is to determine the impact of remote ischemic preconditioning on dynamic cerebral autoregulation and related hematology indexes in healthy adults.

remote ischemic preconditioning(ripc) is the phenomenon whereby brief cycles of ischemia and reperfusion, applied to a distant organ, provide protection to the target organ. dynamic cerebral autoregulation(dca), a mechanism to maintain the cerebral blood flow, has been proved to be critical for the occurrence,development and prognosis of ischemic neurovascular disease. in this study, we hypothesis that ripc provides neuro-protection by means of improving dca.

Eligibility criteria:
inclusion criteria: * age from 18 to 70,both genders * willing to participate in follow-up visits exclusion criteria: * current or having a history of chronic physical diseases or mental diseases * suffering from infectious diseases in late one month * pregnant and lactating women； * smoking or drinking； * inability to cooperate sufficiently to complete the dca examination

Keywords: ischemic preconditioning dynamic cerebral autoregulation